Listed by the USPTO as JACKSON, SHAWQUIA
Tech Center 1600 • Art Units: 1623 1626 1629
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555154 | RETINOL FORMULATION (III) | Non-Final OA | DSM IP ASSETS B.V. |
| 18938730 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Non-Final OA | Board of Regents, The University of Texas System |
| 18849279 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | Non-Final OA | Duke University |
| 18839079 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Non-Final OA | Bristol-Myers Squibb Company |
| 18864098 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18938453 | MODULATORS OF TREX1 | Non-Final OA | Constellation Pharmaceuticals, Inc. |
| 18812872 | COMPOUNDS, COMPOSITIONS AND METHODS | Non-Final OA | Denali Therapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy78.1% of resolved applications examined by Shawquia Jackson were allowed (1,848 resolved cases), compared with 51.0% across Art Unit 1623 over the last five years.
This examiner's interview lift is -3.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Shawquia Jackson took 834 days on average from filing to allowance.
Shawquia Jackson examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).